Notice: This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends EDGE vs. FULC, DMAC, ATAI, NLTX, ZNTL, ACRV, ACRS, BMEA, SBTX, and XBITShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Fulcrum Therapeutics (FULC), DiaMedica Therapeutics (DMAC), Atai Life Sciences (ATAI), Neoleukin Therapeutics (NLTX), Zentalis Pharmaceuticals (ZNTL), Acrivon Therapeutics (ACRV), Aclaris Therapeutics (ACRS), Biomea Fusion (BMEA), Silverback Therapeutics (SBTX), and XBiotech (XBIT). These companies are all part of the "medical" sector. Edge Therapeutics vs. Fulcrum Therapeutics DiaMedica Therapeutics Atai Life Sciences Neoleukin Therapeutics Zentalis Pharmaceuticals Acrivon Therapeutics Aclaris Therapeutics Biomea Fusion Silverback Therapeutics XBiotech Edge Therapeutics (NASDAQ:EDGE) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends. Does the media refer more to EDGE or FULC? In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Edge Therapeutics. MarketBeat recorded 4 mentions for Fulcrum Therapeutics and 0 mentions for Edge Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.62 beat Edge Therapeutics' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Edge Therapeutics Neutral Fulcrum Therapeutics Positive Is EDGE or FULC more profitable? Fulcrum Therapeutics' return on equity of -7.31% beat Edge Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edge TherapeuticsN/A -81.29% -56.92% Fulcrum Therapeutics N/A -7.31%-6.74% Which has more volatility and risk, EDGE or FULC? Edge Therapeutics has a beta of 3.65, meaning that its share price is 265% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Do analysts rate EDGE or FULC? Fulcrum Therapeutics has a consensus price target of $9.33, suggesting a potential upside of 114.56%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Edge Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edge Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the MarketBeat Community believe in EDGE or FULC? Edge Therapeutics received 79 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 66.79% of users gave Edge Therapeutics an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformEdge TherapeuticsOutperform Votes17766.79% Underperform Votes8833.21% Fulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% Do insiders & institutionals have more ownership in EDGE or FULC? 28.0% of Edge Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 37.1% of Edge Therapeutics shares are held by company insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, EDGE or FULC? Edge Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdge TherapeuticsN/AN/A-$40.86MN/AN/AFulcrum Therapeutics$80.87M2.90-$97.33M-$0.31-14.03 SummaryFulcrum Therapeutics beats Edge Therapeutics on 9 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.99M$6.57B$5.10B$9.07BDividend YieldN/A2.97%4.90%4.21%P/E RatioN/A10.5591.0817.15Price / SalesN/A195.381,113.51116.81Price / CashN/A57.1642.2637.86Price / Book1.745.104.784.78Net Income-$40.86M$151.51M$119.77M$225.60M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/A$1.65-5.7%N/A-65.8%$51.99MN/A0.00N/AFULCFulcrum Therapeutics1.7405 of 5 stars$4.42+11.6%$9.33+111.2%-22.6%$238.41M$80.87M-13.68100DMACDiaMedica Therapeutics0.8393 of 5 stars$5.31-1.3%$7.00+31.8%+141.0%$227.06MN/A-9.4820News CoverageGap DownATAIAtai Life Sciences1.8723 of 5 stars$1.33-2.2%$9.00+576.7%-9.8%$223.18M$331,000.00-1.6883Positive NewsNLTXNeoleukin TherapeuticsN/A$23.51+5.3%N/A+532.5%$220.95MN/A-7.5690News CoverageHigh Trading VolumeZNTLZentalis Pharmaceuticals2.0012 of 5 stars$3.10+0.3%$10.00+222.6%-77.9%$220.91MN/A-1.24160ACRVAcrivon Therapeutics0.9637 of 5 stars$7.00-0.8%$23.67+238.1%+41.0%$217.95MN/A-2.6158News CoverageACRSAclaris Therapeutics3.8453 of 5 stars$3.02-6.2%$8.80+191.4%+190.9%$215.72M$27.08M-5.8386BMEABiomea Fusion3.8965 of 5 stars$5.85+3.7%$39.36+572.9%-69.2%$212.00MN/A-1.4150Analyst ForecastSBTXSilverback TherapeuticsN/A$11.89-0.2%N/A+116.0%$211.66MN/A-4.9183News CoverageGap UpHigh Trading VolumeXBITXBiotechN/A$6.92-0.4%N/A+61.9%$210.94M$4.01M-6.41100 Related Companies and Tools Related Companies Fulcrum Therapeutics Competitors DiaMedica Therapeutics Competitors Atai Life Sciences Competitors Neoleukin Therapeutics Competitors Zentalis Pharmaceuticals Competitors Acrivon Therapeutics Competitors Aclaris Therapeutics Competitors Biomea Fusion Competitors Silverback Therapeutics Competitors XBiotech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDGE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDGE Stock Alerts